glp-1 digital health platforms startups Consumers Taking GLP-1s for Weight Loss, Current or Discontinued, Drive Lasting Changes in Retail, Per New Acosta Group Study Q1 2026 funding overview: Capital

Key Takeaways The medical field primarily uses Semaglutide to manage adults with type 2 diabetes or dealing with obesity or being overweight

Cody Fair, chief commercial officer at Noom, told Fierce Healthcare that employers and payers are looking for a program that works beyond simply making GLP-1s available to patients and that takes a whole-person approach to obesity

Intake, labs, prescriptions, and ongoing coaching are all handled through one easy-to-use app

Sarawi WS, Alhusaini AM, Fadda LM, Alomar HA, Albaker AB, Aljrboa AS, et al

Make sure your choice offers robust insurance and prior authorization help, as Klinic does, removing hurdles many clinics leave patients to face on their own